US equities |
SPCX $173.94 ▲+1.67% NVDA $241.88 ▲+1.25% MU $1,065.61 ▲+0.16% AMD $657.38 ▲+4.06% MRVL $291.65 ▲+7.52% SNDK $1,674.62 ▼-1.73% AVGO $378.05 ▲+4.29% TSLA $380.49 ▲+0.46%
FinancialContent

Apimeds Pharmaceuticals US, Inc. Common Stock (NY:APUS)

6.500 +1.910 (+41.61%)
Delayed Quote Updated: 11:19 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apimeds Pharmaceuticals US, Inc. Common Stock

< Previous 1 2 3 Next >
News headline image
Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
From The Rosen Law Firm, P.A.
Via Business Wire
MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
Via CryptoCurrencyWire
Topics Artificial Intelligence Economy
MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence Economy
News headline image
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
From Apimeds Pharmaceuticals US, Inc.
Via GlobeNewswire
News headline image
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
From Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
< Previous 1 2 3 Next >